NTHI - NASDAQ

Neonc Technologies Holdings, Inc.

NTHI·NASDAQ

$4.35

-4.2%

HealthcareBiotechnology

Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$86.98M

EPS-3.2300

P/E Ratio-1.35

Earnings Date06/03/2026

nthi

Total Non-Current Liabilities

Last Annual Value

290.68K

3-Year CAGR

5-Year CAGR

10-Year CAGR

Adjust for Inflation

Neonc Technologies Holdings, Inc. Competitors Analysis of Total Non-Current Liabilities

NTHI · NASDAQ

Company	Total Non-Current Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Neonc Technologies Holdings, Inc. NASDAQ:NTHI	290.68K	N/A	N/A	N/A
Armata Pharmaceuticals, Inc. AMEX:ARMP	286.53M	36.0%	48.6%	50.2%
Invivyd, Inc. NASDAQ:IVVD	1.18M	-6.0%	150.3%	N/A
OmniAb, Inc. NASDAQ:OABI	17.63M	-22.3%	-18.7%	N/A
SELLAS Life Sciences Group, Inc. NASDAQ:SLS	457.00K	-0.2%	-16.1%	-23.6%
Assembly Biosciences, Inc. NASDAQ:ASMB	2.06M	-66.8%	-19.4%	-15.5%
Corbus Pharmaceuticals Holdings, Inc. NASDAQ:CRBP	0.00	N/A	N/A	N/A
Genelux Corporation NASDAQ:GNLX	1.26M	-12.3%	-41.7%	N/A
Sangamo Therapeutics, Inc. NASDAQ:SGMO	31.55M	-3.1%	-32.1%	14.1%
Protara Therapeutics, Inc. NASDAQ:TARA	2.12M	-22.1%	-19.8%	N/A
Orchestra BioMed Holdings, Inc. NASDAQ:OBIO	34.74M	29.6%	-13.7%	N/A

Neonc Technologies Holdings, Inc. Fair Value Envelope

NTHI · NASDAQ

Our analysis suggests that NTHI has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.35, this represents a potential HIDDEN relative to our calculated worth for Neonc Technologies Holdings, Inc..

HIDDEN

Intrinsic Value

Current Price: $4.35

Related Guides

Blog Categories

Continue your NTHI research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.